Lifecore Biomedical, Inc. \De\ (LFCR) Asset Writedowns and Impairment (2015 - 2024)

Lifecore Biomedical, Inc. \De\'s Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at -$1.4 million for Q2 2024.

• In Q2 2024, Asset Writedowns and Impairment fell 240.2% year-over-year to -$1.4 million; the TTM figure through May 2024 stood at $2.0 million (down 95.93% YoY), while the FY2023 annual figure was $1.3 million, down 98.34% from the prior year.
• Asset Writedowns and Impairment for Q2 2024 stood at -$1.4 million, down from $1.4 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $46.1 million in Q2 2022, with the low at -$1.4 million in Q2 2024.
• The 5-year median for Asset Writedowns and Impairment is $591000.0 (2021), against an average of $6.7 million.
• The sharpest annual moves came in 2021 and 2024: Asset Writedowns and Impairment soared 47656.72% in 2021, then tumbled 240.2% in 2024.
• Lifecore Biomedical, Inc. \De\'s Asset Writedowns and Impairment stood at $67000.0 in 2020, then jumped by 47656.72% to $32.0 million in 2021, then plunged by 96.87% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then sank by 240.2% to -$1.4 million in 2024.
• Business Quant data shows LFCR's Asset Writedowns and Impairment at -$1.4 million in Q2 2024, $1.4 million in Q1 2024, and $1.0 million in Q2 2023.